Pediatric non-alcoholic fatty liver disease and kidney function: Effect of HSD17B13 variant

Table 3 General linear model for analysis of variance of estimated glomerular filtration rate both among patients with and without non-alcoholic fatty liver disease

Source	Patients with NAFLD			Patients without NAFLD
	Coefficient	F-ratio	P value	Coefficient	F-ratio	P value
Model		6.24	< 0.0001		3.30	0.001
Gender	-0.78	0.62	0.43	0.31	0.09	0.75
Duration of obesity	-2.48	6.17	0.01	-0.47	0.22	0.63
HSD17B13 genotype	1.89	42.58	< 0.0001	4.63	21.49	< 0.0001
PNPLA3 genotype	-3.80	11.19	0.001	-0.90	0.81	0.36
TM6SF2 genotype	1.13	11.82	0.001	1.40	1.97	0.16
BMI-SDS	0.62	0.38	0.53	0.51	0.26	0.61
HOMA-IR	-1.20	1.44	0.23	0.63	0.40	0.52
Triglycerides	-0.94	0.89	0.34	0.95	0.90	0.34
LDL-Cholesterol	0.69	0.47	0.49	0.23	0.05	0.81

NAFLD: Model r2 0.39, adjusted r2 0.33; Non NAFLD: Model r2 0.16, adjusted r2 0.11. ALT: Alanine transaminase; BMI: Body mass index; eGFR: Estimated glomerular filtration rate; GLM: General linear model; HOMA: Homeostasis model assessment; LDL: Low density lipoprotein; SDS: Standard deviation score.